Skip to main content

Table 3 Baseline Characteristics of Subset 2 data by Group

From: A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps

  MOMH
(N = 64)
Placebo
(N = 65)
P Value
Demographics
Gender Female n (%) 52 (81.3) 51 (78.5) 0.827
Age (years) mean (±SD) 60.4 (±10.9) 59.1 (±10.1) 0.517a
Weight (kg) mean (±SD) 75.1 (±11.8) 74.3 (±13.1) 0.583
Height (cm) mean (±SD) 165.9 (±7.7) 166.2 (±7.8) 0.278
BMI (kg/m2) mean (±SD) 27.3 (±4.1) 26.9 (±4.8) 0.395a
Physiological parameters
Systolic blood pressure (mmHg) mean (±SD) 127.6 (±10.9) 127.7 (±9.6) 0.826a
Diastolic blood pressure (mmHg) mean (±SD) 78.8 (±6.7) 77.5 (±6.2) 0.154a
Heart rate (beats/min) mean (±SD) 72.0 (±6.9) 71.7 (±6.6) 0.749a
Baseline efficacy parameters
NLC frequency (num/week) mean (±SD) 5.8 (±5.7) 7.3 (±9.5) 0.753a
NLC duration (sec/week) mean (±SD) 311.4 (±242.9) 340.7 (±247.1) 0.410a
NLC pain (mean VAS/week) mean (±SD) 6.5 (±1.6) 6.8 (±1.5) 0.252
Sleep quality (mean cumulative score/week) mean (±SD) 13.0 (±3.7) 12.5 (±3.8) 0.451
Quality of life subscales:
- Physical functioning 58.6 (±24.2) 60.2 (±26.9) 0.934a
- Role limitation due to physical health 38.3 (±44.5) 40.8 (±43.4) 0.616a
- Role limitation due to emotional problems 37.0 (±44.9) 33.9 (±43.1) 0.696a
- Vitality 45.4 (±14.2) 45.5 (±12.4) 0.783a
- Mental health 49.2 (±13.8) 49.2 (±12.0) 0.879a
- Social functioning 60.4 (±15.7) 57.7 (±15.3) 0.457a
- Body Pain 46.0 (±18.2) 46.0 (±17.7) 0.921a
- General health 44.3 (±13.1) 45.4 (±8.8) 0.580a
  1. BMI body mass index, MOMH magnesium oxide monohydrate, NLC nocturnal leg cramps, SD standard deviation, VAS visual analogue scale
  2. Note: Variables marked with a were not normally distributed. ANOVA and ANCOVA on ranks were performed for comparisons of these variables